• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5074212)   Today's Articles (191)
For: Park J, Lee JB, Lim MC, Kim BG, Kim JW, Kim S, Choi CH, Kim HS, Park SY, Lee JY. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D. J Immunother Cancer 2023;11:e007444. [PMID: 37865397 PMCID: PMC10603354 DOI: 10.1136/jitc-2023-007444] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/22/2023] [Indexed: 10/23/2023]  Open
Number Cited by Other Article(s)
1
Park J, Joung JG, Lim MC, Lee J, Kim BG, Kim JW, Shin SJ, Kim S, Park E, Choi CH, Kim HS, Park SY, Lee JY. Neoadjuvant Chemotherapy with Dual Immune Checkpoint Inhibitors for Advanced-Stage Ovarian Cancer: Final Analysis of TRU-D Phase II Nonrandomized Clinical Trial. Clin Cancer Res 2025;31:1865-1876. [PMID: 40043003 DOI: 10.1158/1078-0432.ccr-24-3753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2024] [Revised: 01/12/2025] [Accepted: 03/03/2025] [Indexed: 05/16/2025]
2
Zhong S, Wu W, Liang Y, Wu Z. Prognostic significance and therapeutic outcome prediction through serum miR-21 and miR-145 in ovarian cancer. AN ACAD BRAS CIENC 2025;97:e20240565. [PMID: 40243761 DOI: 10.1590/0001-3765202520240565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/18/2025]  Open
3
Connor A, Lyons P, Kilgallon A, Simpson J, Perry A, Lysaght J. Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer. Heliyon 2024;10:e38888. [PMID: 39640610 PMCID: PMC11620064 DOI: 10.1016/j.heliyon.2024.e38888] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2024] [Accepted: 10/01/2024] [Indexed: 12/07/2024]  Open
4
Min KJ, Kim NK, Song JY, Choi MC, Lee SW, Lee KH, Kim MK, Kang S, Choi CH, Lee JW, Lee EJ, Eom KY, Kim SW, Cho H, Lee SJ, Lim MC, Bae J, Yoo CW, Kim K, Kim DY, Lee C, Ryu SY, Jeon S, Kim JW, Nam BH, Kang SB, Kim KT, Nam JH, Kim BG, Kim YM, Kim JH. From the Beginning of the Korean Gynecologic Oncology Group to the Present and Next Steps. Cancers (Basel) 2024;16:3422. [PMID: 39410040 PMCID: PMC11475356 DOI: 10.3390/cancers16193422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2024] [Revised: 09/24/2024] [Accepted: 10/08/2024] [Indexed: 10/20/2024]  Open
5
Larionova I, Iamshchikov P, Kazakova A, Rakina M, Menyalo M, Enikeeva K, Rafikova G, Sharifyanova Y, Pavlov V, Villert A, Kolomiets L, Kzhyshkowska J. Platinum-based chemotherapy promotes antigen presenting potential in monocytes of patients with high-grade serous ovarian carcinoma. Front Immunol 2024;15:1414716. [PMID: 39315092 PMCID: PMC11417001 DOI: 10.3389/fimmu.2024.1414716] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Accepted: 08/20/2024] [Indexed: 09/25/2024]  Open
6
Satora M, Kułak K, Zaremba B, Grunwald A, Świechowska-Starek P, Tarkowski R. New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment-a narrative review. Front Pharmacol 2024;15:1416555. [PMID: 38948462 PMCID: PMC11212463 DOI: 10.3389/fphar.2024.1416555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2024] [Accepted: 05/29/2024] [Indexed: 07/02/2024]  Open
7
Han J, Lyu L. Identification of the biological functions and chemo-therapeutic responses of ITGB superfamily in ovarian cancer. Discov Oncol 2024;15:198. [PMID: 38814534 PMCID: PMC11139846 DOI: 10.1007/s12672-024-01047-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2024] [Accepted: 05/20/2024] [Indexed: 05/31/2024]  Open
8
Shim SH, Lee JY, Lee YY, Park JY, Lee YJ, Kim SI, Han GH, Yang EJ, Noh JJ, Yim GW, Son JH, Kim NK, Kim TH, Kong TW, Choi YJ, Cho A, Lim H, Jang EB, Cho HW, Suh DH. Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer. J Gynecol Oncol 2024;35:e66. [PMID: 38330382 PMCID: PMC10948978 DOI: 10.3802/jgo.2024.35.e66] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2024] [Revised: 01/16/2024] [Accepted: 01/16/2024] [Indexed: 02/10/2024]  Open
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA